Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins

American Journal of Clinical Pathology

Volumn 139, Issue 2, 2013, Pages 192-200

  Leschik, Johannes J ^a   Diana, Tanja ^a   Olivo, Paul D ^b   König, Jochem ^c   Krahn, Ulrike ^c   Li, Yunsheng ^b   Kanitz, Michael ^a   Kahaly, George J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Quidel Corporation   (United States)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Analytical performance; Dilution analysis; Thyroid stimulating immunoglobulins

Indexed keywords

ANTITHYROID AGENT; AUTOANTIBODY; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN RECEPTOR; BIOLOGICAL MARKER; THYROTROPIN BINDING INHIBITORY IMMUNOGLOBULIN; THYROTROPIN-BINDING INHIBITORY IMMUNOGLOBULIN;

ADULT; AGED; BIOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; TITRIMETRY; ANIMAL; ARTICLE; BLOOD; CHO CELL; CLINICAL TRIAL; COMPARATIVE STUDY; CRICETULUS; DOSE RESPONSE; HAMSTER; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; REPRODUCIBILITY;

ADULT; AGED; ANIMALS; ANTITHYROID AGENTS; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; LIMIT OF DETECTION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84875076139     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPZUT7CNUEU7OP     Document Type: Review

References (32)

1. Brent GA. Graves' disease. N Engl J Med. 2008;358:2594-2605.
2. Rose NR. Predictors of autoimmune disease: Autoantibodies and beyond. Autoimmunity. 2008;41:419-428.
3. Mizutori Y, Chen CR, Latrofa F, et al. Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease. J Clin Endocrinol Metab. 2009;94:927-935.
4. Davies TF, Yin X, Latif R. The genetics of the thyroid stimulating hormone receptor: History and relevance. Thyroid. 2010;20:727-736.
5. Zöphel K, Roggenbuck D, Schott M. Clinical review about TRAb assay's history. Autoimmun Rev. 2010;9:695-700.
6. Lytton SD, Kahaly GJ. Bioassays for TSH-receptor autoantibodies: An update. Autoimmun Rev. 2010;10:116-122.
7. Morris JC III, Hay ID, Nelson RE, et al. Clinical utility of thyrotropin-receptor antibody assays: Comparison of radioreceptor and bioassay methods. Mayo Clin Proc. 1988;63:707-717.
8. Ponto KA, Kanitz M, Olivo PD, et al. Clinical relevance of thyroid-stimulating immunoglobulins in Graves' ophthalmopathy. Ophthalmology. 2011;118:2279-2285.
9. Lytton SD, Ponto KA, Kanitz M, et al. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J Clin Endocrinol Metab. 2010;95:2123-2131.
10. Lytton SD, Li Y, Olivo PD, et al. Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol. 2010;162:438-446.
11. Sanders J, Evans M, Premawardhana LD, et al. Human monoclonal thyroid stimulating autoantibody. Lancet. 2003;362:126-128.
12. Schott M, Hermsen D, Broecker-Preuss M, et al. Clinical value of the first automated TSH receptor auto-antibody assay for the diagnosis of Graves' disease (GD): An international multicentre trial. Clin Endocrinol (Oxf). 2009;71:566-573.
13. Tholen DW, Linnet K, Kondratovich M, et al. Protocols for Determination of Limits of Detection and Limits of Quantitation. Approved Guideline. Wayne, PA: National Committee for Clinical Laboratory Standards; 2004. NCCLS EP17-A.
14. Brain P, Cousens R. An equation to describe dose responses where there is stimulation of growth at low dose. Weed Res. 1989;29:93-96.
15. Finney DJ. Bioassay and the practice of statistical inference. Int Stat Rev. 1979;47:1-12.
16. Kamijo K, Murayama H, Uzu T, et al. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroidstimulating hormone receptor binding assay in Graves' disease. Thyroid. 2011;21:1295-1299.
17. Kamijo K, Murayama H, Uzu T, et al. A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (Mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid. 2010;20:851-856.
18. Evans M, Sanders J, Tagami T, et al. Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample. Clin Endocrinol (Oxf). 2010;73:404-412.
19. Yoshimura Noh J, Miyazaki N, Ito K, et al. Evaluation of a new rapid and fully automated electrochemiluminiscence immunoassay for thyrotropin receptor autoantibodies. Thyroid. 2008;18:1157-1164.
20. Hermsen D, Eckstein A, Schinner S, et al. Reproducibility of Elecsys anti-TSHR test results in a lot-to-lot comparison. Horm Metab Res. 2010;42:295-297.
21. Latif R, Morshed SA, Zaidi M, et al. The thyroid-stimulating hormone receptor: Impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am. 2009;38:319-341.
22. Núñez Miguel R, Sanders J, Chirgadze DY, et al. Thyroid stimulating autoantibody M22 mimics TSH binding to the TSH receptor leucine rich domain: A comparative structural study of protein-protein interactions. J Mol Endocrinol. 2009;42:381-395.
23. Sanders J, Jeffreys J, Depraetere H, et al. Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: Sequence structure and function. Thyroid. 2004;14:560-570.
24. Rees Smith B, Sanders J, Evans M, et al. TSH receptorautoantibody interactions. Horm Metab Res. 2009;41:448-455.
25. Schott M, Minich WB, Willenberg HS, et al. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease. Horm Metab Res. 2005;37:741-744.
26. Schott M, Minich WB, Willenberg HS, et al. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res. 2004;36:92-96.
27. Wallaschofski H, Miehle K, Mayer A, et al. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment. Horm Metab Res. 2002;34:383-388.
28. Michelangeli V, Poon C, Taft J, et al. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid. 1998;8:119-124.
29. Michelangeli VP, Munro DS, Poon CW, et al. Measurement of thyroid stimulating immunoglobulins in a new cell line transfected with a functional human TSH receptor (JPO9 cells), compared with an assay using FRTL-5 cells. Clin Endocrinol (Oxf). 1994;40:645-652.
30. Michelangeli VP, Poon CW, Arnus EE, et al. Measurement of TSH receptor blocking immunoglobulins using 3H-adenine incorporation into FRTL-5 and JPO9 cells: Use in a child with neonatal hypothyroidism. Clin Endocrinol (Oxf). 1995;42:39-44.
31. Vitti P, Chiovato L, Lopez G, et al. Measurement of TSAb directly in serum using FRTL-5 cells. J Endocrinol Invest. 1988;11:313-317.
32. Wallaschofski H, Paschke R. Detection of thyroid stimulating (TSAB)-and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH-receptor numbers. Clin Endocrinol (Oxf). 1999;50:365-372.